Related Experiment Video

Updated: Dec 10, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated

MeganS Farris1, Kelly A Larkin-Kaiser1, Tayler Scory1

  • 1Medlior Health Outcomes Research Ltd, Calgary, AB, T2C 5P9, Canada.

Future Oncology (London, England)
|September 2, 2020
PubMed

Insights

Dacomitinib demonstrates improved overall survival in advanced EGFR+ NSCLC patients. This epidermal growth factor receptor-targeted tyrosine kinase inhibitor should be considered a first-line treatment option.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced non-small-cell lung cancer (NSCLC) with EGFR mutations presents treatment challenges.
  • Epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFR TKIs) are a key therapeutic strategy.

Purpose of the Study:

  • To update overall survival (OS) results from a network meta-analysis.
  • To compare the relative clinical efficacy of first-line EGFR TKIs for EGFR mutation-positive (EGFR+) advanced NSCLC.

Main Methods:

  • A Bayesian network meta-analysis was performed.
  • Updated and mature overall survival data from randomized controlled trials were utilized.

Main Results:

  • Dacomitinib showed a numerical improvement in OS compared to other EGFR TKIs.
  • Specific hazard ratios (HR) and 95% credible intervals (CrI) were reported for comparisons against afatinib, erlotinib, gefitinib, and osimertinib.

Conclusions:

  • Dacomitinib is a potential first-line treatment option for advanced EGFR+ NSCLC.
  • The findings support considering dacomitinib for this patient population.
Keywords:
EGFREGFR mutation positiveTKInetwork meta analysisnon-small-cell lung canceroverall survivaltyrosine kinase inhibitors

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
562
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K